Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

NCT02375022 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Endostar and icotinib

Sponsor

Zhejiang University

Collaborators

[object Object]
[object Object]